Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.60 |
| ▸ | THPO | P40225 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | NPY1R | P25929 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | NPY2R | P49146 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13975578 | 1.00 | LMNA (0.60) | LMNASLC29A1TSHRNFKB1THPO | |
| SCHEMBL29617834 | 1.00 | LMNA (0.60) | LMNASLC29A1TSHRNFKB1THPO | |
| SCHEMBL314051 | 1.00 | LMNA (0.60) | LMNASLC29A1TSHRNFKB1THPO | |
| SCHEMBL9294393 | 1.00 | LMNA (0.60) | LMNASLC29A1TSHRNFKB1THPO | |
| SCHEMBL18521420 | 1.00 | LMNA (0.60) | LMNASLC29A1TSHRNFKB1THPO | |
| SCHEMBL314052 | 1.00 | LMNA (0.60) | LMNASLC29A1TSHRNFKB1THPO | |
| SCHEMBL23621389 | 1.00 | LMNA (0.60) | LMNASLC29A1TSHRNFKB1THPO | |
| SCHEMBL314050 | 1.00 | LMNA (0.60) | LMNASLC29A1TSHRNFKB1THPO | |
| SCHEMBL21625242 | 1.00 | LMNA (0.60) | LMNASLC29A1TSHRNFKB1THPO | |
| SCHEMBL25748736 | 1.00 | LMNA (0.60) | LMNASLC29A1TSHRNFKB1THPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230146410-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2023-05-11 | — | — | US | disclosed |
| EP-3724205-B1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH INC (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20210340169-A1 | CYCLIC DINUCLEOTIDE COMPOUND AND USES THEREOF | SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) | 2021-11-04 | — | — | US | disclosed |
| US-20210009630-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-14 | — | — | US | disclosed |
| EP-3724205-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | Janssen Biotech, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019118839-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN BIOTECH, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146410-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, MAVS | LMNA 636/4885SLC29A1 2830/4885TSHR 2236/4885 |
| US-20210009630-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | LMNA 356/4885SLC29A1 2658/4885TSHR 2468/4885 |
| US-20210340169-A1 | CYCLIC DINUCLEOTIDE COMPOUND AND USES THEREOF | STING1, CGAS, TLR9 | LMNA 2541/4885SLC29A1 442/4885TSHR 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.